Aerie Pharmaceuticals, Inc. (AERI)
| Market Cap | 457.00M |
| Revenue (ttm) | 104.15M |
| Net Income (ttm) | -166.48M |
| Shares Out | 47.36M |
| EPS (ttm) | -3.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,914,091 |
| Open | 9.92 |
| Previous Close | 9.76 |
| Day's Range | 9.26 - 9.93 |
| 52-Week Range | 9.15 - 21.30 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 23.13 (+139.7%) |
| Earnings Date | Nov 4, 2021 |
About AERI
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is al...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for AERI stock is "Buy." The 12-month stock price forecast is 23.13, which is an increase of 139.69% from the latest price.
News
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Reg...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopress...
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...
Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y
Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of -16.13% and 0.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provid...
Aerie Pharmaceuticals (AERI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, announced today that its third quarter 2021 financial results will be released after the ...
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Tom Mitro, President and Chief Operating Officer presented an overvi...
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Tr...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company's Phase 3 clinical trial in Japan ...
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overv...
Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina ...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant...
Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman an...
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Dispo...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...
Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study
Aerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15.
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...
Aerie (AERI) Down 0.9% Since Last Earnings Report: Can It Rebound?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
Aerie's(AERI) Q2 Loss Wider Than Expected, Revenues Beat
Aerie (AERI) incurs wider-than-expected loss in the second quarter of 2021 but sales beat expectations.
Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of -3.08% and 2.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...
Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...
Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...